, Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden, Cancer Causes Control, vol.26, issue.11, pp.1627-1669, 2015.
, Acute lymphoblastic leukemia: a comprehensive review and 2017 update, Blood Cancer Journal, vol.7, issue.6, p.577, 2017.
, Treatment of adult acute lymphoblastic leukemia, Semin Hematol, vol.46, issue.1, pp.64-75, 2009.
, Modern therapy of acute lymphoblastic leukemia, J Clin Oncol, vol.29, issue.5, pp.532-575, 2011.
, Detection of minimal residual disease in acute lymphoblastic leukemia, Atlas of genetics and cytogenetics in oncology and haematology, 2009.
, Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia, Blood, vol.107, issue.3, pp.1116-1139, 2006.
, Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL), Blood, vol.113, issue.18, pp.4153-62, 2009.
, Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies, Blood, vol.120, issue.9, pp.1868-76, 2012.
, Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The polish adult leukemia group ALL 4-2002 MRD study, Br J Haematol, vol.142, issue.2, pp.227-264, 2008.
, Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993, Br J Haematol, vol.148, issue.1, pp.80-89, 2010.
, Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia, Br J Haematol, vol.172, issue.3, pp.392-400, 2016.
DOI : 10.1111/bjh.13834
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.13834
, Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a metaanalysis, JAMA Oncology, vol.3, issue.7, p.170580, 2017.
, Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia, Leuk Res Treatment, p.421723, 2014.
, Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia, Blood Cancer J, vol.4, p.225, 2014.
, Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia, Haematologica, vol.92, issue.5, pp.612-620, 2007.
, BMC Cancer, vol.18, p.1100, 2018.
, Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL, Bone Marrow Transplant, vol.48, issue.3, pp.396-402, 2013.
, Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.27, issue.5, pp.69-82, 2016.
DOI : 10.1093/annonc/mdw025
URL : https://academic.oup.com/annonc/article-pdf/27/suppl_5/v69/6677631/mdw025.pdf
, Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial, J Clin Oncol, vol.32, issue.15, pp.1595-604, 2014.
, Acute lymphoblastic leukemia (ALL): 2012 Guideline, 2012.
, for the GRAALL Scientific Board. A randomized multicenter Phase III study to compare the efficacy of HyperC to standard induction and late intensification in younger adults with de novo Philadelphia chromosomenegative acute lymphoblastic leukemia (ALL), 2005.
, Treatment of Adult ALL According to Protocols of the German Multicenter Study Group for Adult ALL (GMALL), in Acute Leukemias, pp.167-176, 2008.
, UKALL14: A randomized trial for adults with newly diagnosed acute lymphoblastic leukemia
, Improving the quality of web surveys: the checklist for reporting results of internet E-surveys (CHERRIES), J Med Internet Res, vol.6, issue.3, p.34, 2004.
, AIRC ALL guideline, 2016.
, Interdisciplinary guidelines of the German cancer society and the society for pediatric oncology and hematology, AWMF, 2014.
, ALL 0904 protocol: intensification of post-remissional treatment of high-risk acute lymphoblastic leukemia in adults and minimal residual disease monitoring, 2004.
, On behalf of the GIMEMA Acute Leukemia Working Party. Monitoring of minimal residual disease in adult acute lymphoblastic leukemia patients without known genetic abnormalities: impact on prognosis in the GIMEMA LAL-0904 protocol, Haematologica, vol.94, issue.2, p.p, 2009.
, Further tests for ALL, 2016.
, Guideline long term condition Support Leukemia acute adults. 2012. 30. Initiative, I.X., Scientific basis for guidelines ALL guideline, HAS, 2016.
, Clinicla practice guidelines in oncology acute lymphoblastic leukemia version 2, 2015.
, The role of MRD diagnostics in guiding therapy in acute lymphoblastic leukemia, 39th EBMT Meeting, 2013.